.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XL10_NadofarageneFiradenovec.NadofarageneFiradenovec .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XL10_NadofarageneFiradenovec.NadofarageneFiradenovec| name: | NadofarageneFiradenovec | |
| ATC code: | L01XL10 | |
| route: | intravesical | |
| compartments: | 1 | |
| dosage: | 3 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Nadofaragene firadenovec is a recombinant adenoviral vector-based gene therapy that delivers the human interferon alfa-2b gene to the urothelial cells. It is used as a treatment for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) in adults. Nadofaragene firadenovec was approved by the US FDA in 2022 for this indication.
No peer-reviewed pharmacokinetic parameters are published in the literature to date for nadofaragene firadenovec. As a gene therapy administered intravesically, it is primarily localized to the bladder with negligible systemic absorption expected in treated adult patients.